Phase 2 Results: LP-003 Significantly Decreases Chronic Spontaneous Urticaria Disease Activity

Hu F, Wu L, Han C, et al

This was a multicenter, randomized, double-blind, placebo- and active-controlled phase 2 trial evaluating the efficacy and safety of the novel anti-IgE antibody LP-003 versus omalizumab and placebo in patients with refractory chronic spontaneous urticaria. LP-003, particularly at 200 mg (Q8W and pooled regimens), demonstrated statistically significant and clinically meaningful improvements in disease activity (UAS7) compared with omalizumab, with higher rates of complete disease control. The treatment was well tolerated with no drug-related serious adverse events, supporting further development as a potentially more effective anti-IgE therapy for this population.